Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy

Yao-An Shen, Jin Jung, Geoffrey D. Shimberg, ..., Ie-Ming Shih, Chi-Mu Chuang, Tian-Li Wang

Highlights
Developing small molecular compounds to interfere with PBX1 protein and DNA interaction

Lead compound, T417, is potent in affecting PBX1 transcription

T417 displays low in vivo toxicity and satisfactory in vivo anti-tumor potency
Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy

Yao-An Shen,1,2,3 Jin Jung,1,2 Geoffrey D. Shimberg,1,2 Fang-Chi Hsu,1 Yohan Suryo Rahmanto,1,2 Stephanie L. Gaillard,1,2 Jiaxin Hong,1,2 Jürgen Bosch,7,8,* Ie-Ming Shih,1,2,* Chi-Mu Chuang,4,5,6,* and Tian-Li Wang1,2,9,*

SUMMARY
PBX1 is a transcription factor involved in diverse cellular functions including organ development, stem cell renewal, and tumorigenesis. PBX1 is localized at chr1q23.3, a frequently amplified chromosomal region, and it is overexpressed in many human malignancies. Cancer cells with elevated PBX1 signaling are particularly vulnerable to PBX1 withdrawal. We designed a series of small molecule compounds capable of docking to the interface between PBX1 and its cognate DNA target sequence. Among them, T417 is found to be a lead compound. In cell-based assays, T417 significantly suppressed self-renewal and proliferation of cancer cells expressing high levels of PBX1. T417 also re-sensitized platinum-resistant ovarian tumors to carboplatin. T417 did not affect healthy tissues likely due to their lower PBX1 expression levels. Therefore, targeting PBX-DNA interface can be a promising strategy for treating human tumors reliant on PBX1 for survival.

INTRODUCTION
Radical surgery and cytotoxic chemotherapy have extended the survival of patients suffering from advanced cancer, but rarely achieved a long-term remission because most patients eventually developed resistance to the prior chemotherapeutic agents. Ovarian high-grade serous carcinoma (HGSC) is one such example as the disease remains one of the most lethal types of female reproductive cancer because of resistance to the prior chemotherapeutic agents. Surprisingly, genome-wide analysis has not identified prevalent example as the disease remains one of the most lethal types of female reproductive cancer because of resistance to the prior chemotherapeutic agents. Ovarian high-grade serous carcinoma (HGSC) is one such advanced cancer, but rarely achieved a long-term remission because most patients eventually developed resistance to the prior chemotherapeutic agents.

PBX1 encodes a TALE (3-amino acid loop extension) class homeodomain transcription factor and regulates gene expression in both developmental and self-renewal pathways (Ficara et al., 2008; Selleri et al., 2001). The contribution of PBX1 to human cancer was first reported in childhood acute lymphoblastic leukemia which is triggered by chromosomal translocations between the PBX1 locus at chr1q23 and the E2A locus at chr19p13.3, resulting in a PBX1-E2A fusion product with oncogenic potential (Kamps et al., 1991; Melentin et al., 1990). Subsequently, PBX1 overexpression was found in solid tumors including melanoma, prostate, breast, gastric, and esophageal cancers (He et al., 2017; Kikugawa et al., 2006; Magnani et al., 2015; Risolino et al., 2014; Shiraiishi et al., 2007; Yeh et al., 2009; Zhu et al., 2017). In breast cancer, PBX1 reprograms estrogen receptor (ER) α-positive cells, inducing them to become refractory to ER antagonist therapy (Magnani et al., 2013). This largely explains why a PBX1 signaling signature in patients with ER-positive breast cancer predicts a worse clinical outcome (Magnani et al., 2013). In ovarian cancer, PBX1 has...
been shown to participate in maintaining cancer stem cell-like phenotypes and promoting resistance to platinum anti-cancer drugs, at least partially through its intricate interaction with the NOTCH signaling network (Jung et al., 2016; Park et al., 2006, 2010). PBX1 mRNA upregulation in ascites recurrent tumors obtained from patients previously treated with chemotherapy also correlated with a worse overall survival (Jung et al., 2016). Collectively, the accumulated data indicate that PBX1 is an integral component of the core stem cell network and can be “hijacked” for tissue repair and cell re-population processes when a tumor encounters environmental change or stress, such as those imposed by chemotherapy (Jung et al., 2016). In view of this, we sought to determine whether targeting PBX1 pathway using a small molecule inhibitor could resensitize cancer cells with upregulated PBX1 to chemotherapy.

Unfortunately, oncogenic transcription factors including PBX1 have fallen into an “undruggable” category because most transcription factors mediate their action by protein-DNA interaction rather than by enzymatic activities (Dang et al., 2017). Nevertheless, our study challenges the aforementioned view as it exemplifies the application of structure biology in guiding rational design for targeting the seemingly undruggable targets. PBX1 functions as a transcription factor by directly interacting with DNA and orchestrating the transcription of an array of target genes (Blasi et al., 2017; Jung et al., 2016; Thiaville et al., 2012). Owing to a lack of intrinsic enzymatic activity, small molecule targeting of PBX1 should be directed toward the disruption of PBX1 transcriptional complexes. Structural studies of the PBX1-containing transcriptional complex have shown that PBX1 interacts with a DNA target motif (5'-TGATT-3') through its conserved hydrophobic pocket (LaRonde-LeBlanc and Wolberger, 2003; Piper et al., 1999). We designed chemical scaffolds which are predicted to bind to the moiety on the PBX1 protein that interacts with the target DNA motif sequences. Using the electrophoretic mobility shift assay (EMSA) and cellular thermal shift assay (CETSA), we identified a lead small molecule inhibitor that potently bound PBX1 protein and prevented the formation of the PBX1 transcription complex. We further found that this lead compound was PBX1 specific, displayed minimal toxicity, and inhibited the growth of tumor xenografts with PBX1 overexpression. Our results demonstrate that PBX1 is an actionable molecular target in human cancers that depend on the PBX1 signaling pathway for survival. The study provides insights to the strategic design of small molecules targeting the PBX1 transcriptional complex and suggests chemical structures of potential interest for future optimization, development, and testing.

RESULTS
Expression of PBX1 in ovarian carcinomas and correlation with NOTCH3 expression
Although PBX1 is known to be involved in organ development, its expression in adult tissues remains unclear. We measured PBX1 expression by western blot analysis and observed that most adult normal tissues, including the liver, lung, heart, thyroid gland, and kidney tissues, expressed relatively low levels of PBX1 compared with carcinoma tissues from the ovary (HGSC) (Figure 1A). We noted that the ovary and pancreas expressed relatively higher levels of PBX1 compared with other organs. This could be attributed to engagement of PBX1 in the development of the urogenital tract (Schnabel et al., 2003). We also surveyed PBX1 expression in normal and malignant tissues derived from a genetically engineered mouse (GEM) model of gynecologic cancers, mogo-Tag. In this GEM model, the mice develop uterine and ovarian malignancies as a result of the SV40 large T-antigen (TAg) expression under the control of the oviduct-specific glycoprotein (OVGP1) promoter. PBX1 expression was elevated in the uterine and fallopian tube tumors from the mogo-Tag mice compared with other normal counterpart tissues acquired from wild-type mice (Figure 1B). The expression level of MOEX1, a direct transcriptional target of PBX1 (Thiaville et al., 2012), was also examined, and its expression was positively associated with PBX1 expression across various organs and tissues (Figure 1B). Since ovarian cancer is a heterogeneous group of diseases consisting of 5 histologic types characterized by distinct clinicopathological and molecular features (Cho and Shih Ie, 2009), we also performed PBX1 western blot analysis on three different types of human ovarian carcinomas (clear cell carcinoma, low-grade serous carcinoma, and HGSC). We found increased expression of PBX1 in significant fractions of high-grade and low-grade ovarian serous carcinomas compared with ovarian clear cell carcinoma (Figure S1).

We previously reported PBX1 protein upregulation in chemoresistant/recurrent ovarian tumors compared with primary tumors from the same patients (Jung et al., 2016; Park et al., 2008). Although analysis of PBX1 mRNA expression in primary ovarian tumors using TCGA ovarian cancer data does not predict clinical outcomes, PBX1 protein expression measured by immunohistochemistry correlates with worse survival in recurrent ovarian cancer (Jung et al., 2016).
Tumor (nuclear) grade has been established as an important factor affecting clinical outcome in ovarian serous carcinomas (Kurman and Shih Ie, 2016). Based on the Kaplan-Meier (K-M) plotter portal (Gyorffy et al., 2012), we analyzed PBX1 expression and clinical outcome in women with ovarian serous cancers. To avoid post-surgical residual tumor volume as a confounding factor in outcome studies, the analysis was focused on optimally cytoreduced and debulked cases (Bristow et al., 2002; Wimberger et al., 2010). In patients with lower-grade tumors (grades 1 and 2), we found that PBX1 overexpression levels were significantly associated with worse overall survival on the basis of two PBX1 probes (Id 205263 and Id 212148). The result using one of the probes is shown in Figure 1C. On the other hand, PBX1 expression in ovarian high-grade serous tumors is not clearly associated with the overall survival outcome.

Previous studies have also implicated PBX1 signaling in promoting malignant behaviors of breast cancer (Magnani et al., 2015). Using multiple breast cancer datasets in K-M plotter, researchers of previous studies demonstrated that PBX1 expression could correlate with clinical outcome (Magnani et al., 2013). Here, we evaluated the association of PBX1 expression and clinical outcomes for four main breast cancer subtypes

**Figure 1. PBX1 expression in normal tissues and its prognostic impact for ER+ breast cancers**

(A) Western blots of various human adult tissues and organs. Ovarian high-grade serous carcinomas (HGSCs) were included for comparison.

(B) Left: Western blots (from the same exposure time of the films) for PBX1 expression in normal tissues from mogp-Tag mice. Transformed cells in the uterus and fallopian tubes manifested higher PBX1 expression compared with normal tissues from the same mice. Right: Representative images of uterus and fallopian tubes from a wild-type control mouse and a mogp-Tag mouse.

(C) Kaplan-Meier analysis of the ovarian serous cancer data obtained from the KM plot portal. PBX1 expression (microarray probe Id 205253) in lower-grade serous tumors (grades 1 and 2) at the advanced stages was analyzed for its effect on the overall survival. Upper panel: analysis performed on tumor stages 3 + 4, lower panel: analysis performed on tumor stages 2 + 3 + 4.

(D) Kaplan-Meier survival analysis of breast cancer data obtained from the TCGA portal. PBX1 and ER expression levels in breast tumors were used to separate patients into four groups as indicated. (E) Statistical significance levels of the survival distributions in (D) analyzed by the Mantel-Cox test.
PBX1-targeting compounds destabilize the PBX1-DNA interaction

Structural studies have shown that PBX1 interacts with the DNA sequence motif (5’-TGATT-3’) through its conserved peptide sequences (Hawkins et al., 2010). Therefore, we synthesized a series of small molecules that were predicted to dock between the PBX1 protein and DNA binding interface (Figures 2A and S2A). Using EMSA, we evaluated the capacity of these compounds to destabilize the PBX1-DNA complex. In this assay, purified recombinant PBX1 protein was incubated with biotin-labeled DNA probes containing the PBX1 binding motif sequences. The addition of compounds T417, T418, and T383 to the reaction mixtures potently interfered with the PBX1-DNA interaction in a dose-dependent manner, achieving an IC₅₀ of 6.58 μM (T417), 7.98 μM (T418), and 5.04 μM (T383) (Figure 2B). The chemical structures and biochemical properties of additional analogs, including the prodrug DH82, are summarized in Figure S2A. In this assay, 293T cells were transfected with a plasmid vector expressing full-length PBX1 cDNA with a V5 epitope tag (Figure S2B). The nuclear extracts were purified and incubated with a panel of small molecule analogs. EMSA analysis showed that these compounds did not interfere with the PBX1 protein-DNA interaction (Figure S2C).

We then performed cellular thermal shift assay (CETSA) to assess the thermal stability of PBX1 protein-drug complexes. We found that the fraction of PBX1 protein bound by T417 at any given temperature was higher than the fraction of PBX1 bound by any of the other analogs, including T418 and T383 (Figure 3). For example, at a temperature of 58°C, more than 50% of PBX1 protein remained bound by T417, whereas less than 50% of PBX1 protein remained bound by the other analogs (Figures 3B and 3C). These data indicated that all small molecule compounds tested, binding of T417 to PBX1 protein resulted in the most stable complex.

Next, we used surface plasmon resonance (SPR)-based biomolecular interaction technology to determine the binding affinity of PBX1 protein to DNA containing the PBX1 consensus binding motif. Biotin-tagged double-stranded DNA probes, the same probes used for EMSA assays, were immobilized on a Biacore sensor chip that was coated with neutravidin. Increasing concentrations of purified recombinant PBX1 protein were passed over the DNA-bound chip surface, and kinetic parameters of the binding interaction between PBX1 protein and DNA probes were measured. We determined that PBX1 protein bound to DNA probes containing the PBX1 binding motif with a KD of 0.8 nM (ka = 1.654 × 10⁴/Ms, kd = 1.311 × 10⁻³/s). In contrast, PBX1 protein bound to the negative control DNA probes without PBX1 motif with more than four orders of magnitude weaker affinity (KD = 11.19 μM, kₐ = 1.100 × 10⁵/Ms, k₈ = 1.231 × 10⁻⁴/s) (Figure 3D).

We next assessed whether small molecule PBX1 inhibitors would interfere with PBX1 protein-DNA binding using the SPR method. Eight different small molecule analogs (T417, D59, 649D4, B70, 649B54, B63, DHP, and GSI) at 10 μM concentration were premixed with PBX1 protein and injected over the same chip surface that was coated with DNA probes harboring PBX1 binding motif. Only T417 was able to reduce PBX protein binding to DNA. The remaining 7 analogs did not have a significant impact on PBX binding to DNA (Figure 3E). We then performed a competition titration experiment with increasing concentrations of T417 (0.625–80 μM) against a constant PBX1 protein concentration (10 nM). As T417 concentration increased, PBX1 binding to the DNA decreased in a dose-dependent manner (Figure 3F). When the percent competition values were plotted against T417 concentrations, we were able to predict an approximate 5 μM binding affinity between T417 and PBX1 protein.

Computational docking suggests that T417 binds to the DNA binding groove of PBX1

For virtual docking studies, PBX1 structures were retrieved from the Protein Data Bank using accession numbers 1B72 and 1PUF (LaRonde-LeBlanc and Wolberger, 2003; Piper et al., 1999). The OpenEye suite of programs was employed throughout the study (McGann, 2012). The receptor was prepared using OEDocking 3.2.0.2 with default values without defining interaction constraints. The region for docking was selected to comprise the entire area of the DNA binding site. Conformers of T417 were prepared using OMEGA2.5.1.4 (Hawkins et al., 2010), which generated a total of 4,031 conformers. Docking was carried out by examining the TCGA dataset. In the ER-positive breast cancer subtype, PBX1 upregulation was associated with worse clinical outcomes than ER-positive breast cancer subtype with low PBX1 expression (p = 0.029, logrank test; Figure 1D). By contrast, PBX1 expression levels did not correlate with clinical outcomes in the ER-negative breast cancers (Figure 1D) or in other subtypes of breast cancers. The significance levels of the statistical tests are summarized in Figure 1E.
on a 1-Å fine grid (highest resolution) using FRED software (McGann, 2012) with otherwise default parameters. Twenty poses with the highest Chemgaus4 scores were retained for individual inspection. The best pose, which exhibited a Chemgaus4 score, represented a conformation in which most hydrogen bonds were formed between T417 and PBX1 protein (Video S1 and Figure 2A). Five hydrogen bonds were formed between T417 and PBX1 protein, which not only stabilized the compound in the DNA binding groove but also contributed to the selectivity. Additionally, the naphthalene ring formed favorable hydrophobic interactions with the side chain of Ile 289.

Chemgaus4 docking scores for other analogs developed in this study are shown in Table 1. The analogs developed in the current study in general showed similar docking scores, suggesting that the chemical backbone structure is dominant in conferring properties contributing to the score calculation matrix. Therefore, future biophysical experiments such as SPR are critical for better understanding of the drug-PBX1 complex interaction and binding affinity of analogs reported in the current study.
T417 selectively suppresses the formation of the PBX1/MEIS2 transcriptional complex

In addition to forming homo-oligomer complexes, PBX1 can interact with other members of the homeo-domain family to form hetero-homeodomain complexes, which orchestrate transcriptional regulation in...
mammalian cells (LaRonde-LeBlanc and Wolberger, 2003). To determine the capacity of T417 to destabilize the PBX1/MEIS2 hetero-complex, we performed EMSA analysis and generated DNA oligonucleotide probes containing both MEIS2 and PBX1 binding motifs. As controls, mutant DNA oligonucleotide probes, in which the PBX1 or MEIS2 binding motif was mutated, were created (Figure 4A). Purified PBX1 and/or MEIS2 protein was incubated with wild-type or mutant DNA probes as indicated in Figure 4B. When adding only PBX1 or MEIS2 protein to the EMSA reaction mixture containing the wild-type probes, we observed a specific band corresponding to the homo-complex in the EMSA assay (lanes 2 and 3 of the left panel). On the other hand, when both PBX1 and MEIS2 were added to the mixture, a higher molecular weight band, likely corresponding to the PBX1/MEIS2/DNA hetero-complex, was evident in lane 4. In EMSA assays using PBX1 or MEIS2 motif mutant probes (middle and right panels, respectively), we only observed the lower molecular weight bands corresponding to the homo-complex (lanes 7 and 10). Most importantly, the co-addition of PBX1 and MEIS2 proteins to the mutant probe mixtures did not form a hetero-complex (lanes 8 and lane 12) as it did in the wild-type probe group (lane 4).

The PBX1-MEIS-DNA hetero-complex was validated by the supershift assay in which the reaction was incubated with PBX1 or MEIS1 antibody. The fact that almost all of the detected complexes (bands) were supershifted by either anti-PBX1 or anti-MEIS1 antibody indicates that the detected band is a hetero-complex containing both PBX1 and MEIS1 proteins (Figure 4C), rather than a homo-complex containing exclusively the Pbx1 or Meis1 protein. When T417 was added to the EMSA, the formation of the PBX1-MEIS-DNA tertiary complex was abated in a dose-dependent fashion (Figure 4D). In fact, the IC50 of the PBX1-MEIS-DNA tertiary complex was similar to that of the PBX1-DNA complex.

| Table 1. Molecular docking analysis of compounds developed in this study |
|-----------------------------------------------|
| Name   | Molecular weight | Chemgaus4 docking score a | Solubility (XLogP b ) | Polar surface area |
|--------|------------------|---------------------------|-----------------------|--------------------|
| 649D-38 | 431.4            | –4.61                     | 2.8                   | 100.5              |
| DH-HP-0052 | 430.4        | –5.54                     | 3.8                   | 87.7               |
| TCRS-417 | 446.4            | –5.27                     | 3.1                   | 107.9              |
| TCRS-418 | 446.4            | –4.84                     | 3.1                   | 107.9              |
| TCRS-383 | 462.4            | –4.58                     | 2.5                   | 128.1              |
| TCRS-388 | 482.5            | –4.19                     | 2.8                   | 125.0              |

aDocking score more negative, energetically more favored.
bThe XLogP value describes the solubility of the compound in a water-octane mixture. A large positive value indicates it is more soluble in octane than water.

T417 inhibits PBX1 transcriptional activity by hindering its binding to the promoter regions of PBX1 downstream target genes

To determine whether T417 inhibits PBX1 transcriptional activity, we performed a promoter reporter assay in which the promoter of MEOX1 was cloned upstream to the firefly luciferase gene in the pGL3 plasmid (Thiaville et al., 2012). HEK-293T cells transfected with this reporter plasmid and a control plasmid containing the Renilla luciferase were exposed to PBX1 inhibitor analogs. PBX1 inhibitor T417 and, to a lesser extent, T418, compromised PBX1-mediated transcriptional activity in a dose-dependent manner (Figure 5A). A chromatin immunoprecipitation (ChIP)-qPCR assay was performed to determine whether the compound blocked the binding of PBX1 protein to its target promoter sequences. We found that T417 or T418 treatment notably reduced the occupancy of the PBX1 protein to its target promoters compared with the prodrug DH82 or DMSO vehicle control (Figure 5B). T417 and T418 also reduced the expression of these PBX1 target genes (Figure 5C).

PBX1 expression levels in cancer cells correlate with their response to PBX inhibitors

To assess whether PBX1 activity or its expression level in cancer cells was predictive of the cellular response to PBX1 inhibition, we measured PBX1 expression levels on a panel of 28 cancer cell lines (most of them derived from the ovarian neoplasms) and determined their response to PBX1 inhibitors (T417, T418) and the control prodrug DH82. We found a positive correlation between PBX1 expression and T417 sensitivity ($r = –0.555$, $p < 0.001$) (Figure 5D). The correlation between PBX1 expression and T418 sensitivity was marginal ($r = –0.16$). By contrast, there was no correlation between PBX1 expression and its response to
prodrug DH82 (Figure 5D). We repeated these experiments in primary ovarian cancer cell cultures and found a similar trend, indicating that the expression levels of PBX1 in tumors are associated with their response to PBX1 inhibitor, T417 ($r = -0.64; p < 0.01$) (Figure 5E).

Next, we compared the PBX1-regulated transcriptome between T417-treated and untreated cells. The PBX1-regulated transcriptome was identified and defined by differential expression between PBX1 small interfering RNA (siRNA)- and control siRNA-treated OVCAR3 cells (false discovery rate q value < 0.1 and fold change >2). This PBX1-regulated transcriptome was compared against T417-affected transcriptomes by gene set enrichment analysis (Subramanian et al., 2005) (Figure 5F). The enrichment was significant with a normalized enrichment score (NES) of $1.308$ ($p < 0.0001$). We also compared gene sets available at the Molecular Signature Database (Broad Institute), including stem cell factors NANOG, OCT4, SOX2, and MYC, ES cell signature, and PBX1 target set against the T417 transcriptomes. This independent PBX1 target gene set, together with many of the stemness factors, are significantly enriched in the T417-regulated transcriptomes (NES values summarized in Figure 5G), further supporting the capability of T417 in inhibiting PBX1 transcriptional activity.

**PBX1 inhibitors re-sensitize carboplatin-resistant cells to platinum-based chemotherapy**

To facilitate mechanistic studies of PBX1 inhibitors, we established carboplatin-resistant (CR) and taxol-resistant (TR) variants of OVCAR3 and SKOV3 ovarian cancer cell lines. Western blot analysis showed that PBX1 expression levels were upregulated in OVCAR3-CR and SKOV3-CR CR cells compared with the corresponding TR or parental cell variants (Figure 6A). As predicted, CR cells were more vulnerable to T417 treatment than were the TR or parental cells (Figure 6B). These results further support the hypothesis that PBX1 expression levels predict the cellular response to PBX1 inhibition. On the other hand, the
Figure 5. PBX inhibitors suppress PBX1 transcriptional activities

(A) PBX1 transcriptional activity was assessed using a MEOX1 luciferase promoter reporter transfected into 293T cells. MEOX1 is a direct transcriptional target gene of PBX1 previously identified by our group (Thiaville et al., 2012).

(B) The in vivo occupancy of target promoters by PBX1 was assessed by ChIP-qPCR analysis. OVCAR3 carboplatin-resistant cells were treated with 2.5 μM PBX inhibitors or vehicle (DMSO). PCR primers were designed to flank the peak of the PBX1-bound promoter of each target gene identified previously by our group (Thiaville et al., 2012). PCR was performed in triplicate wells and normalized to the input control.

(C) OVCAR3 cells were incubated with PBX1 inhibitors for 24 h. qRT-PCR was performed using gene-specific primers, and data were normalized to the expression level of a housekeeping gene, APP.

(D and E) Cytotoxicity assays in ovarian cancer cells using PBX1 inhibitors. Ovarian cancer cell lines (D) and primary cells derived from OVCA patient samples (E) were incubated with serial concentrations of PBX1 inhibitors for 48 h. The relative numbers of live cells were determined by a CellTiter Blue assay kit and were normalized to cell numbers obtained in the absence of an inhibitor. IC50 values were calculated using GraphPad Prism software; PBX1 expression was determined by western blot analysis. Each data point represents the relative PBX1 expression level and IC50 value in each cell line. r represents the Pearson’s correlation coefficient.

(F) Gene set enrichment analysis (GSEA) demonstrates that PBX1-regulated genes are enriched in the T417 inhibitor-regulated transcriptome. PBX1-regulated genes are identified through differential analysis of RNA transcripts in PBX1 siRNA-treated and control siRNA-treated OVCAR3 cells. In total there are 1,868 genes (p < 0.01, fold change >2 cutoff). This PBX1-regulated gene set was compared against the T417 inhibitor-regulated transcriptome by GSEA and found to correlate with the T417-inhibited transcriptome. NES, normalized enrichment score.

(G) GSEA was also utilized to evaluate the enrichment of stem cell factor, ES cell, and PBX1 target gene signatures in the T417 inhibitor-regulated expression profile. The gene signature sets were downloaded from Molecular Signatures Database at the Broad Institute.
The difference in the IC₅₀ between OVCAR3 naive and CR cells was less significant, most likely due to the high endogenous expression levels of PBX1 in parental OVCAR3 cells.

We previously showed that PBX1 promoted stem cell-like traits including the capability for long-term self-renewal in a suspension culture environment, resulting in high potency of spheroid formation. We evaluated the effect of the T417 PBX1 inhibitor on the formation of tumor spheroids of the CR ovarian cancer cell lines, OVCAR3-CR and SKOV3-CR, in a three-dimensional (3D) microtissue culture model that closely mimics the in vivo structure of a tumor mass (Chen et al., 2010). We found that T417 attenuated their spherogenic capacity and re-directed stem cell-like cells back to a more differentiated state (Figure 6C). By a quantitative analysis of 3D spheroids to drug sensitivity, we observed that T417 significantly re-sensitized OVCAR3-CR (p = 0.0066) and SKOV3-CR cells (p = 0.0108) to carboplatin (Figure 6D).

**Figure 6. PBX inhibitor selectively inhibits carboplatin-resistant tumor cells**

(A) Western blot analysis of PBX1 expression by OVCAR3 and SKOV3 naive, carboplatin-resistant (CR) and paclitaxel-resistant (TR) cells. The inhibitor was incubated for 48 h, and cell viability was measured using a CellTiter blue assay.

(B) Cell viability of SKOV3 and OVCAR3 naive, CR, and TR cells under a serial concentration of T417. T417 was incubated for 48 h, and cell viability was measured using a CellTiter blue assay.

(C) Spherogenic capacity of OVCAR3-CR and SKOV3-CR cells treated with T417.

(D) SKOV3 and OVCAR3 naive and CR cells were treated with a serial concentration of carboplatin combined with or without T417. Cell viability was measured using a CellTiter-Glo 3D assay and was normalized to the viability of cells in the absence of an inhibitor.

**T417 sensitizes platinum-resistant xenograft tumors to chemotherapy**

The aforementioned results indicated that cancer cells with PBX1 upregulation may rely on the PBX1 pathway for survival. Therefore, they would likely be susceptible to PBX1 inhibition. To determine the suitability of T417 for in vivo studies, we examined the potential toxicity of T417 in mice. Mice received 3 doses/week of T417 at 5 mg/kg over a course of 3 weeks (Figure S3A). We did not observe significant differences in hematologic or clinical chemistry profiles between T417-treated and DMSO-treated mice (Figure S3B). In addition, we did not observe lethargy, weight loss, or notable physical morbidity (Figure S4A). Necropsy was performed, and there was no sign of tissue damage or histological abnormalities on major organs and tissues, including brain, heart, lung, liver, spleen, kidney, and intestine (Figures S4B, S4C, and S5). Collectively, these in vivo experiments indicate that T417 displayed minimal toxicity in mice. We also tested the effects of T417 on PBX1 downstream target genes and found that intratumoral injection of T417 reduced MEOX1 and BCL6 gene expression in a dose-dependent manner (Figure S6).

We next tested whether T417 alone or in combination with carboplatin suppressed the growth of PBX1-overexpressing tumor xenografts such as A2780 and SKOV3-CR, when compared with parental SKOV3 (Figure 7A). To facilitate in vivo imaging of parental SKOV3 and SKOV3-CR cells, the cells were transfected with a luciferase expression vector and stable clones were established. Bioluminescence was inspected 5 days after tumor cell
inoculation, and mice with similar basal levels of bioluminescence were selected for the experiments. The regimen involved 3 cycles of 3 days on and 3 days off drug treatment (Figure S7). Parental SKOV3 xenografts did not respond to T417 or vehicle treatment (Figures 7B and 7C). In contrast, T417 alone or in combination with carboplatin resulted in prolonged disease remission and reduced tumor growth in SKOV3-CR xenografts (Figures 7D and 7E). Furthermore, T417-treated SKOV3-CR tumors but not parental SKOV3 tumors exhibited downregulated PBX1 transcriptional targets genes, MEOX1 and BCL6 (Figures 7C and 7E).

PBX1high colorectal cancer cells, A2780, were subcutaneously injected into immunocompromised nu/nu mice. Six days after tumor cell inoculation, mice were subjected to PBX1 inhibitor treatment following the same protocol for SKOV3-CR cells. We found that the combination of carboplatin and T417 significantly delayed tumor growth and reduced the end point tumor weight of A2780 xenografts compared with the single agent or vehicle control-treated groups (Figure 7F). To evaluate the effect of T417 on PBX1 signaling in xenografts, the expression of PBX1 target genes, MEOX1 and BCL6, was examined by qRT-PCR. Consistent with the cell culture data shown in Figure 5C, T417 reduced their mRNA levels (Figure 7G).

**DISCUSSION**

Resistance to cancer therapy including chemotherapy, targeted therapy and hormone therapy remains a formidable obstacle for achieving long-term remission or cure in patients with cancer. Resistant cells
harness specific metabolic states and/or alterations in DNA repair pathways to survive from cytotoxic damage induced by the therapeutic agents. Previous work by our group and others has established a fundamental link between the PBX1 signaling network and refractoriness to current therapies for human ovarian cancer and ER-positive breast cancer. These findings have set the stage for developing small molecule inhibitors targeting PBX1 signaling to combat treatment failures and improve survival in patients with these malignancies. Our data reported here show a net upregulation of the PBX1 axis in cancer cells or tissues that was not evident in a wide range of normal tissues, suggesting that PBX1 is potentially an appropriate target for cancer therapy. Supporting this view, the PBX1 inhibitor, T417, reported in this study was well-tolerated at a therapeutic dose and had minimal toxicity in mice, indicating its promise as an anticancer agent for further development and evaluation.

Our study demonstrates the feasibility of a strategy aimed at directly interfering with the interaction between PBX1 protein and DNA target sequences using a structure-based design of small molecule compounds. The specificity of the lead compound, T417, in destabilizing the PBX1-DNA complex is supported by multiple lines of evidence. First, the analysis of the interaction between PBX1 proteins and small molecules by a thermal stability shift assay indicated that T417 displays a greater binding affinity to PBX1 protein compared with its analogs evaluated in this study. The data support that T417 docking at the DNA binding groove on the PBX1 protein surface may cause destabilization of the PBX1-DNA complex. Second, T417 demonstrates a strong potency in interfering with the binding between PBX1 protein and its cognate DNA binding sequences based on SPR and EMSAs. Similarly, in vivo interaction between PBX1 and its target gene promoter sequences assessed by ChIP-qPCR is potently inhibited by T417 but not by other PBX inhibitor analogs. Third, computational docking analysis showed that T417 might form a specific hydrogen bonding network combined with hydrophobic interactions with specific DNA sequence motifs. Moreover, the superiority of T417 to the earlier compound, D46, a close relative of T417, was evident from a side-by-side computational docking comparison between the two. The Chemgaus4 docking score of T417 with PBX1 was −5.16, which was significantly better (p < 0.001) than the D46 docking score (−2.34) under identical docking conditions (Sterling and Irwin, 2015). Fourth, comparing PBX1 target genes to the T417-regulated transcriptome further established a significant enrichment of PBX1 target genes that are regulated by T417. Collectively, the aforementioned evidence lends further support to the specificity and potency of T417 in suppressing PBX1-regulated transcription.

Results from the current study suggest that PBX1 levels alone or in combination with other markers may predict the clinical outcome in specific types of human cancer. Moreover, based on the observations that PBX1 levels are associated with the cellular response to PBX1 inhibition, as T417 selectively suppresses the growth of PBX1-overexpressing tumor cells in both the 3D spheroids and in xenograft tumor models, PBX1 levels may have the potential to be explored as a predictive marker for response to PBX1 inhibitors. To the best of our knowledge, T417 represents the first successful class of compounds that inhibits tumor growth by directly interfering with PBX1 transcriptional activities and suppressing its biological activities. Compared with peptide-based approaches, direct targeting of the PBX1-DNA interface by small molecule compounds is a relatively new concept that could potentially bypass metabolic instability, poor membrane penetration, limited oral bioavailability, and adverse immune response that are commonly associated with peptide-based drugs (Marqus et al., 2017).

The mechanisms by which PBX1 inhibition re-sensitizes tumor cells to platinum and hormone therapy are not clear, but our previous analysis of PBX1-regulated target genes provides important clues. Using siRNA knockdown, we profiled the PBX1-regulated transcriptome in ovarian cancer cells and found that the glutathione (GSH) and estrogen signaling pathways are positively regulated by PBX1 (Jung et al., 2016). GSH is an essential cellular redox buffering system. High intracellular levels of glutathione are a major contributing factor to chemoresistance. GSH acts by binding to or reacting with drugs, interacting with reactive oxygen species, or preventing damage to proteins or DNA (Hawkins et al., 2010). Therefore, antagonizing the glutathione pathway via PBX1 inhibition can, in principle, sensitize tumor cells to platinum-based chemotherapy.

Our results presented here have several implications pertaining to translational applications of PBX1 inhibitor-based therapy. First, we established a new approach to target the PBX1 signaling network. The lead compound presented here can be exploited as a molecular probe for investigating the physiological and pathological processes related to PBX1. Second, the expression levels of PBX1 in cancer cells were
found to correlate with their response to PBX inhibitor T417. These results warrant further investigation into whether PBX1 levels can serve as a companion biomarker to identify patients who will most likely respond to PBX1-based therapy. Third, in addition to ovarian cancer, it would be invaluable to test PBX1 inhibition in ER+ breast cancer and other human malignancies with PBX1 signaling activation. Because PBX1 transcription is thought to play a role in developmental disorders, neurodegeneration, and autoimmune diseases (Dang et al., 2017), the PBX1 signaling inhibitor developed here may have versatile applications for these disorders. Considering the promising results presented in this study, future efforts to assess the safety, determine the efficacy, and chemically optimize the performance of this class of PBX1 inhibitors for clinical testing are warranted.

Limitations of the study
This report is limited by the lack of crystallography studies. Testing anti-tumor efficacy of the lead inhibitor on other PBX1-dependent malignancies warrants further investigation.

STAR Methods
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Material availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHODS DETAILS
  - Electrophoretic mobility shift assay (EMSA)
  - Cellular thermal shift assay
  - Computational analysis
  - Luciferase reporter assay and drug treatment
  - Chromatin immunoprecipitation (ChIP) analysis and qPCR
  - Validation of short interfering RNA knockdowns by quantitative real-time PCR
  - Western blot
  - Tumor sphere formation assay
  - Drug sensitivity and cell viability assay
  - Primary and chemoresistant ovarian cancer xenograft model
  - Surface plasmon resonance
  - Kaplan-Meier analysis of PBX1 expression and patients clinical outcome
- QUANTIFICATION AND STATISTICAL ANALYSIS

Supplemental Information
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103297.

Acknowledgments
This work was supported by the NIH grants R01CA148826, R01CA215483, R21CA187512, and P50CA228991; the Department of Defense grants W81XWH-11-2-0230 and W81XWH-14-1-0221; the Ovarian Cancer Research Alliance award; the Maryland Innovation Initiative MII (TEDCO); the Bisciotti Foundation Translational Fund; the Richard W. TeLinde endowment from the Department of Gynecology and Obstetrics, Johns Hopkins University, and the TEAL Award. G.D.S. is a recipient of the T32 fellowship award (NIH/NIA T32AG058527). We thank Biacore Molecular Interaction Shared Resource at Georgetown University, which is partially supported by NIH grant P30CA051008 and S10 shared instrument grants 1S10OD019982-01 and 1S10RR022388-01.

Author Contributions
Y.-A.S., J.J., G.D.S., Y.S.R., and J.H. conducted the experiments described in the paper. J.B. conducted computational screening. F.-C.H. performed RNA-seq bioinformatics analysis. I.-M.S. and T.-L.W. conceived the study and were in charge of the overall study design and research direction. C.-M.C.
Y.-A.S., J.J., G.D.S., S.L.G., I.-M.S., and T.-L.W. wrote the manuscript. All authors reviewed the manuscript, agreed with results, and provided comments on the manuscript.

DECLARATION OF INTERESTS

T.-L.W. is the founder of Ovata, Incov. T.-L.W. and I.-M.S. have a patent related to this work.

INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science.

Accepted: October 14, 2021
Revised: September 10, 2021
Received: April 27, 2021
Published: November 19, 2021

REFERENCES

Blasi, F., Bruckmann, C., Penkov, D., and Dardaei, L. (2017). A tale of TALE, PREP1, PBX1, and MEIS1: Interconnections and competition in cancer. Bioessays 39. https://doi.org/10.1002/bies.201600245.

Bristow, R.E., Tomarczuk, R.S., Armstrong, D.K., Trimble, E.L., and Montz, F.J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248–1259. https://doi.org/10.1200/JCO.2002.3.1248.

Chen, X., Stoeck, A., Lee, S.J., Shih, I.M., Wang, M.M., and Wang, T.L. (2010). Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling pathways in ovarian cancer. Oncotarget 1, 210–218.

Chen, X., Thiaville, M.M., Chen, L., Stoeck, A., Xuan, J.H., Gao, M., Shih, I.M., and Wang, T.L. (2012). Defining NOTCH3 target genes in ovarian cancer. Cancer Res. 72, 2294–2303. https://doi.org/10.1158/0008-5472.CAN-11-2181.

Cho, K.R., and Shih Ie, M. (2009). Ovarian cancer. Annu. Rev. Pathol. 4, 287–313. https://doi.org/10.1146/annurev.pathol.4.110807.092246.

Dang, C.V., Reddy, E.P., Shokat, K.M., and Soucek, L. (2017). Drugging the ‘undruggable’ cancer targets. Nat. Rev. Cancer 17, 502–508. https://doi.org/10.1038/nrc.2017.36.

Ficara, F., Murphy, M.J., Lin, M., and Cleary, M.L. (2008). Pbxi regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence. Cell Stem Cell 2, 484–496. https://doi.org/10.1016/j.stem.2008.03.004.

Gyorffy, B., Lanczky, A., and Szallasi, Z. (2012). Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 19, 197–208. https://doi.org/10.1530/ERC-11-0529.

Hawkins, P.C., Skillman, A.G., Warren, G.L., Ellingson, B.A., and Stahl, M.T. (2010). Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model. 50, 572–584. https://doi.org/10.1021/ci100035x.

He, C.Y., Wang, Z.Q., Zhang, L., Yang, L.Y., Li, J.F., Chen, X.H., Zhang, J., Chang, G., Yu, Y.Y., Liu, B.Y., and Zhu, Z.G. (2017). A hydrophobic residue in the TALE homeodomain of PBX1 promotes epithelial-to-mesenchymal transition of gastric carcinoma. Oncotarget 8, 46818–46833. https://doi.org/10.18632/oncotarget.17473.

Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615. https://doi.org/10.1038/nature10166.

Jafari, R., Almqvist, H., Axelson, H., Ignatushchenko, M., Lundback, T., Nordlund, P., and Molina, D.M. (2014). The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100–2122. https://doi.org/10.1038/nprot.2014.138.

Jung, J.G., Shih, I.M., Park, J.T., Gerry, E., Kim, T.H., Ayhan, A., Handschu, K., Davidson, B., Fader, A.N., Sellier, L., and Wang, T.L. (2016). Ovarian cancer chemoresistance relies on the stem cell reprogramming factor PBX1. Cancer Res. 76, 6351–6361. https://doi.org/10.1158/0008-5472.CAN-16-0980.

Kamps, M.P., Look, A.T., and Baltimore, D. (1991). The human-T(1-19) translocation in pre-B all produces multiple nuclear E2a-pbx1 fusion proteins with differing transforming potentials. Genes Develop. 5, 358–368. https://doi.org/10.1101/Gad.5.3.358.

Kikugawa, T., Kinugasa, Y., Shiraishi, K., Nanba, D., Nakashiro, K., Tanji, N., Yokoyama, M., and Higashiyama, S. (2006). PLZF regulates pbxl production anterior to posterior. Genes Develop. 20, 177–208. https://doi.org/10.1101/gad.11033030.

LaRonde-LeBlanc, N.A., and Wolberger, C. (2003). Structure of HoxA9 and Pbx1 bound to DNA: hox hexapeptide and DNA recognition anterior to posterior. Genes Develop. 17, 2060–2072. https://doi.org/10.1101/gad.11033030.

Magnani, L., Patten, D.K., Nguyen, V.T., Hong, S.P., Steel, J.H., Patel, N., Lombardo, Y., Fanonato, M., Gomes, A.R., Woodley, L., et al. (2015). The pioneer factor PBX1 is a novel driver of metastatic progression in ERalpha-positive breast cancer. Oncotarget 6, 21878–21891. https://doi.org/10.18632/oncotarget.4243.

Magnani, L., Stoeck, A., Zhang, X., Lanczky, A., Mirabella, A.C., Wang, T.L., Gyoryffy, B., and Lanczky, A. (2013). Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl. Acad. Sci. U S A 110, E1490–E1499. https://doi.org/10.1073/pnas.1219992110.

Marquis, S., Pirogova, E., and Piva, T.J. (2017). Evaluation of the use of therapeutic peptides for cancer treatment. J. Biomed. Sci. 24, 21. https://doi.org/10.1186/s12929-017-0328-x.

McGann, M. (2012). FRED and HYBRID docking performance on standardized datasets. J. Computer-Aided Mol. Des. 26, 897–906. https://doi.org/10.1016/j.jcamd.2012.02.003.

Mellentin, J.D., Nourse, J., Hunger, S.P., Smith, S.D., and Cleary, M.L. (1990). Molecular analysis of the T(I-19) breakpoint cluster region in pre-B-cell acute lymphoblastic leukemias. Genes Chromosomes & Cancer 2, 239–247. https://doi.org/10.1002/gcc.2870020313.

Molina, D.M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E.A., Dan, C., Sreekumar, L., Cao, Y.H., and Nordlund, P. (2013). Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87. https://doi.org/10.1126/science.1233606.

Park, J.T., Chen, X., Trope, C.G., Davidson, B., Shih Ie, M., and Wang, T.L. (2010). Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am. J. Pathol. 177, 1087–1094. https://doi.org/10.2353/ajpath.2010.100316.

Park, J.T., Li, M., Nakayama, K., Mao, T.L., Davidson, B., Zhang, Z., Kurman, R.J., Eberhart, C.G., Shih, I.M., and Wang, T.L. (2006). Notch3 gene amplification in ovarian cancer. Cancer Res. 66, 6312–6318. https://doi.org/10.1158/0008-5472.CANT-05-3610.

Park, J.T., Shih, I.M., and Wang, T.L. (2008). Identification of Pbx1, a potential oncogene, as a
Shen, Y.A., Wang, C.Y., Chuang, H.Y., Hwang, J.J.J., Chi, W.H., Shu, C.H., Ho, C.Y., Li, W.Y., and Chen, Y.J. (2016). CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation. Oncotarget 7, 58351–58366. https://doi.org/10.18632/oncotarget.11113.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U S A 102, 15545–15550. https://doi.org/10.1073/pnas.0506580102.

Zhu, X.M., Wei, L., Bai, Y.Q., Wu, S., and Han, S.Y. (2017). FoxC1 promotes epithelial-mesenchymal transition through PBX1 dependent transactivation of ZEB2 in esophageal cancer. Am. J. Cancer Res. 7, 1642–1653.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| anti-V5 antibody    | Invitrogen | R960-25   |
| anti-FLAG antibody  | Sigma-Aldrich clone M2 | |
| anti-Notch3 antibody| Cell Signaling clone D11B8 | |
| anti-Pbx1 antibody  | Abnova clone M01 | |
| anti-Meox1 antibody | Epitomics T2204 | |
| anti-GAPDH antibody | Cell Signaling clone D16H11 | |
| **Biological samples** | | |
| TCGA Breast Invasive Carcinoma cohort | The Cancer Genome Atlas (TCGA) | dbGaP Study Accession: phs000178 |
| **Chemicals, peptides, and recombinant proteins** | | |
| Recombinant MEIS2 protein | Origene, Rockville, MD | N/A |
| Recombinant PBX1 protein | Origene, Rockville, MD | N/A |
| Clarity™ Western ECL Substrate | BIO-RAD | 1705060 |
| Dynabeads™ Protein G for Immunoprecipitation | Thermo Fisher Scientific | 10003D |
| SYBR® Green I Nucleic Acid Gel Stain | Thermo Fisher Scientific | 57567 |
| Restore™ Western Blot Stripping Buffer | Thermo Fisher Scientific | 21059 |
| **Critical commercial assays** | | |
| LightShift Chemiluminescent EMSA kit | Thermo Fisher Scientific | E33075 |
| NE-PER™ Nuclear and Cytoplasmic Extraction Reagents | Thermo Fisher Scientific | 78833 |
| Dual-Glo Luciferase Assay System | Promega | E2920 |
| QIAquick PCR Purification Kit | Qiagen | 28104 |
| Lipofectamine™ RNAiMAX Transfection Reagent | Thermo Fisher Scientific | 13778075 |
| RNasy Plus Mini Kit | Qiagen | 74134 |
| iScript™ cDNA Synthesis Kit | BIO-RAD | 1708891 |
| CellTiter-Blue® Cell Viability Assay | Promega | G8080 |
| **Experimental models: Cell lines** | | |
| 293T | ATCC | CRL-321 |
| OVCAR3 | ATCC | HTB-161 |
| SKOV3 | ATCC | HTB-77 |
| A2780 | Sigma | 93112519 |
| OAW28 | Sigma | 85101601 |
| OAW42 | Sigma | 85073102 |
| TOV21G | ATCC | CRL-11730 |
| ES-2 | Sigma | CRL-1978 |
| **Oligonucleotides** | | |
| PBX1-F qRT-PCR Primer | CGGAGCTGGAGAAATACGAG | IDT |
| PBX1-R qRT-PCR Primer | CGTGCGTCGAGCTTGGGAA | IDT |
| AR-F qRT-PCR Primer | TTGTGTCAAAAAGCGAAATGG | IDT |

(Continued on next page)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Normal epithelial cell lines and tissue samples, including endometrium, fallopian tube, and ovary, were obtained from the Department of Pathology at the Johns Hopkins Hospital. Cell lines, including 293T, OVCAR3, SKOV3, and A2780, were purchased from ATCC (Rockville, MD). Human endometrial epithelial cells were cultured in RPMI1640 medium supplemented with 15% fetal bovine serum (FBS), non-essential amino acids (GIBCO), HEPES buffer (GIBCO), penicillin-streptomycin (GIBCO), 200 nM estradiol (Sigma-Aldrich), and 50 ng/ml epithelial growth factor (EGF, BD Bioscience) in 0.1% gelatin-coated plates. Cell lines 293T, OSE4, OSE7, OSE10, FT2821, FT105, FT406, OAW28, and OAW42 were cultured in DMEM supplemented with 10% FBS. Other cancer cell lines, including OVTOKO, OVMANA, TOV21G, KOC-7C, JHOC5, ES2, OVISE, OV2008, JHS14, OVCA429, SKOV3, HEY, OVCAR3, OVCAR4, OVCAR5, OVCAR8, and A2780 were maintained in RPMI1640 medium supplemented with 10% FBS. To establish chemoresistant ovarian cancer cells (SKOV3-CR, OVCAR3-CR, and OVCAR8-CR cells), SKOV3, OVCAR3, and OVCAR8 cells were continuously cultivated with 1 μM paclitaxel or 10 μM carboplatin.
METHODS DETAILS

Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific) after transfecting cells with a PBX1-V5 construct (Thiaville et al., 2012). EMSA was performed using a LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. For the PBX1-EMSA, biotinylated-DNA probes targeting the PBX1 binding sites in the promoter regions were generated by Integrated DNA Technology (IDT, Coralville, IA). The detailed method is described in previous studies (Chen et al., 2010; Chen et al., 2012; Park et al., 2010). To observe the inhibition of DNA probe/PBX1 protein complex binding by PBX1-targeting drugs, samples were incubated with a serial concentration of each drug or vehicle control (DMSO) prior to the addition of 20 fmol biotinylated-DNA probe. Additional positive and negative control experiments were performed in which purified recombinant PBX1 and MEIS2 proteins (purchased from Origene, Rockville, MD) were incubated with the same concentrations of each drug and assayed.

Cellular thermal shift assay
The capability of the PBX1-targeting drugs to stabilize the target protein in intact cells was evaluated as previously described (Jafari et al., 2014; Molina et al., 2013). Briefly, PBX1 overexpressing cells (1.6 x 10^7 cells per group) were treated at a final concentration of 50 μM of each compound or vehicle control (DMSO) for 1 h in the CO2 incubator at 37°C. Cells were then trypsinized, collected by centrifuge, and resuspended in 800 μl PBS supplemented with protease inhibitors. Cell suspensions (2 x 10^6 cells in 100 μl) were then distributed into 8 different 0.2 ml PCR tubes. Samples were heated for 3 minutes at 37, 40, 43, 46, 49, 52, 55, or 58°C. Cell lysates were prepared immediately after incubation by 3 freeze-thaw cycles consisting of snap-freezing in liquid nitrogen, thawing at 25°C, and brief vortexing. Cell lysate-containing tubes were centrifuged at 20,000 g for 20 min at 4°C to pellet cellular debris together with precipitated and aggregated proteins. The supernatants with the soluble protein fraction were carefully transferred to a new tube, separated by 4-12% SDS-PAGE, and transferred onto PVDF membranes using a semi-dry apparatus (Bio-Rad, Hercules, CA). Membranes were blocked with 2% non-fat dry milk or with 5% bovine serum albumin (BSA) in TBST (20 mM Tris-HCl, 0.5 M NaCl, 0.1% Tween20) and incubated with antibodies specific for V5 tag (Thermo Fisher Scientific, MA, USA), PBX1 (Abnova, Taipei, Taiwan), and GAPDH. Membranes were washed with TBST and incubated with Horseradish peroxidase-conjugated secondary antibody (Jackson Laboratories, West Grove, PA); signals were detected with ECL solution (Bio-Rad, California, USA). Protein levels on the membrane were quantified by densitometry using Gel-Doc software (Bio-Rad).

Computational analysis
All computational virtual screening was performed on a MacPro cluster with 48 CPUs using the OpenEye software suite. Images were generated using PyMol.

Luciferase reporter assay and drug treatment
Promoter constructs of MEOX1, a downstream gene of PBX1, were generated based on the location of the PBX1 binding motif at -181 bp (TGATGATTAAT) from the TSS. A 1.37 kb DNA fragment containing the MEOX1 promoter region was purchased from Genecopia (Rockville, MD). The promoter DNA was amplified with primers containing Nhe1 and Xho1 sites using Pfu Ultra II polymerase (Agilent) to generate the 0.7 kb truncated form in the pGL3-basic vector. All constructs were confirmed by sequencing (Macrogen, Rockville, MD). Primer sequences are available upon request.

To monitor luciferase activity, 293T and OVCAR3 cells were transfected with pGL3-MX constructs and incubated for 24 h, followed by treatment with PBX1-targeting drugs at the designated concentrations for 24 h. To compensate for variations in transfection efficiency, pRL-Renilla reporter plasmid (Promega) was co-transfected, and luciferase activity was determined by Dual-Glo luciferase reagent (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity.

Chromatin immunoprecipitation (ChIP) analysis and qPCR
To confirm binding inhibition by the drug, chromatin immunoprecipitation (Chip) assays and quantified PCR were performed to amplify the promoter regions of PBX1 downstream genes after drug treatment. The ChIP protocol was modified from a previous study (Jung et al., 2016). Briefly, 1 x 10^7 OVCAR3 cells were treated with 2 μM of each drug for 24h, cross-linked with 1% (vol/vol) formaldehyde for 10 min, lysed
in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0), and sonicated using the Bioruptor (Diagenode, Denville, NJ). Lysates were incubated with anti-PBX1 antibody overnight with rotation at 4°C, pulled down using Protein G magnetic beads (Dynabead, Thermo Fisher Scientific), and eluted by the QIAquick PCR Purification Kit (Qiagen). The precipitated DNA was subjected to quantitative PCR (Bio-Rad iCyclers, MyIQ, IQ4) with primers to amplify the promoter regions of PBX1-downstream genes (Table S1). Fold enrichment was calculated by \( \Delta C(t) \) method and normalized to input according to the formula \( \frac{\Delta C(t)_{\text{IP}}-\Delta C(t)_{\text{input}}}{100} \).

**Validation of short interfering RNA knockdowns by quantitative real-time PCR**

PBX1-specific small interfering RNAs (siRNAs), of PBX1-1 (CCCAGGUAUCAAACUGGUUUGAAA and UUUCCAAACCAGUUUGAUACCUGGG) and of PBX1-2 (GCCAAGAAGUGGGCAUCAGUCU and AGACUGUGAUGCCACUUUCUGGC) were purchased from Invitrogen. Cells were treated with siRNA at a final concentration of 100 nM using Lipofectamine RNAiMAX according to the manufacturer’s instructions (Thermo Fisher Scientific). After 48 h, the cells were harvested for western blot or for RNA isolation (Qiagen RNaseasy kit, Qiagen, Germantown, MD). cDNA was synthesized using 500 ng RNA according to the iScript cDNA Synthesis kit protocol (Bio-Rad). qPCR was performed on a Bio-Rad iCycler (MyIQ, IQ4) and the mean \( C_t \) of the gene of interest was calculated from duplicate measurements and normalized with the mean \( C_t \) of a control gene, APP. The PCR primers used in this study are listed in key resource table.

**Western blot**

To assess PBX1 expression levels in tissues, we collected cells from endometrial epithelial cells (EME), ovarian surface epithelial cells (OSE), fallopian tube epithelial cells (FTE), ovarian clear cell carcinoma (CCC), and low- and high-grade serous carcinoma (LGSC and HGSC). After washing, cells were lysed with lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP40) supplemented with protease inhibitor cocktail (Thermo Scientific). Cell lysates were separated by SDS-PAGE and transferred onto a PVDF membrane by a semi-dry transfer (Bio-Rad). After blocking with 5% non-fat dry milk in TBST (20 mM Tris-HCl, 0.5 M NaCl, 0.1% Tween 20), samples were incubated overnight with anti-PBX1 antibody and subsequently incubated in secondary antibody (Jackson Laboratories, West Grove, PA). After developing with ECL solution (Bio-Rad), PVDF membranes were stripped with Restore Western Blot Stripping Solution (Thermo Scientific) and then re-blotted with anti-GAPDH antibody for the loading control. To calculate PBX1 protein expression levels, the intensity of PBX1 and GAPDH bands were determined using ChemiDoc XRS (Bio-Rad), and levels were calculated using the following formula: \( \frac{\text{Int}_{PBX1}/\text{Int}_{GAPDH}}{\text{lowest(\text{Int}_{PBX1}/\text{Int}_{GAPDH})}} \).

**Tumor sphere formation assay**

Single cell suspensions were prepared by trypsinization, and \( 5 \times 10^4 \) cells were seeded into a 1.2% soft agar coated petri-dish in serum-free RPMI1640 as described previously (Shen et al., 2016). The soft surface renders the cells unable to attach, and tumor spheres are formed after a few days in suspension (Shen et al., 2016). The number of tumor spheres was counted after culture for 10 days.

**Drug sensitivity and cell viability assay**

Cells were seeded in 96-well plates at a density of \( 3 \times 10^3 \) cells/well in triplicate wells, and were treated with a serial concentration of PBX1 inhibitors in 10% FBS-containing culture medium for 48 h. Cell viability was recorded by either fluorescence intensity of 0.1% SYBR green I nucleic acid staining solution (Thermo Fisher Scientific) for attaching cells or Cell Titer-Blue reagent (Promega, Madison, WI) for cells in suspension, using a microplate reader (Fluostar, BMG, Durham, NC). The data are presented as mean ± s.d., calculated from triplicate values, and IC\(_{50}\) was defined as the concentration resulting in a 50% decrease in the number of viable cells. Pearson’s correlation index was calculated using R (Ver 3.0.2) by the intensity ratios of PBX1/ GAPDH expression and percent inhibition by each drug. For the 3D cell viability assay, \( 5 \times 10^3 \) cells/well were seeded into ultra-low attachment 96-well plate in triplicate, and were treated with each drug. After 1-week, relative live cell numbers were determined by a CellTiter-Glo assay (Promega).

**Primary and chemoresistant ovarian cancer xenograft model**

Mice employed in all in vivo experiments including those involving xenograft and transgenic mice were maintained and handled according to the specified approved protocol (MO09M473) and guidelines issued by the Johns Hopkins University Animal Care and Use Committee.
To test in vivo drug efficacy, $3 \times 10^6$ A2780 cells were injected into the subcutaneous region of athymic nu/nu mice. Once tumors reached an average volume of approximately 100–300 mm$^3$, mice were randomized into 4 arms. Mice were treated by i.p. injection with vehicle DMSO (1%), carboplatin (30 mg/kg/injection), T417 (5 mg/kg/injection), or the combination of carboplatin and T417. We followed an intermittent schedule with a regimen of 3 days on and 3 days off for 3 weeks (total of 9 treatments). Drug efficacy was quantified by assessing tumor size and body weight every other day.

For the primary and chemoresistant ovarian cancer xenograft models, $3 \times 10^6$ luciferase-expressing SKOV3 naïve cells or chemoresistant SKOV3-CR-Luc cells were injected subcutaneously into 10 mice/group of 6-week-old athymic nude mice. Baseline luciferase activity was measured at day 5, after which 5 mice in each group were selected for drug treatment. Either T417 (5 mg/kg body weight) or vehicle control (DMSO) was administered (i.p.) beginning on day 6 as indicated below, and tumor size and body weight were recorded every other day. For the chemoresistant mouse model, 7 mice were selected for each treatment. Each group was treated with T417 (5 mg/kg body weight), carboplatin (30 mg/kg body weight), or vehicle (DMSO) using regimen described above. Drug efficacy was quantified by measuring tumor size and body weight every other day, and by weekly examining bioluminescent activity (RLU) using the In Vivo Imaging System (IVIS) by Caliper (Perkin Elmer, Waltham, MS, USA).

Surface plasmon resonance
The primary screen of PBX1 was performed on a Biacore 2000 and Biacore 4000 instrument using a CM5 chip at 25°C. PBX1-CS-DNA-Biotin and EBNA-Control-DNA-Biotin were used as ligands and three were used as analytes to flow over the ligand immobilized surface. Neutravidin (10 mg/ml stock concentration) was diluted in 10 mM sodium acetate buffer at pH 4.5 (1:50 dilution, 0.2 mg/ml diluted concentration) and immobilized on the CM5 chip surface, using standard amine coupling chemistry, to a level of ~17300 RU. PBX1-CS-DNA-Biotin was diluted in PBS-P (20 mM phosphate buffer pH 7.4, 137 mM NaCl, 2.7 mM KCl, 0.05% surfactant P20) buffer (1:500 dilution, 100 nM diluted concentration) and captured on the CM5 chip surface to a level of ~2300 RU. EBNA-Control-DNA-Biotin was diluted in buffer (1:10 dilution, 1 nM diluted concentration) and captured on the CM5 chip surface to a level of ~50 RU. PBS-P was used as the immobilization/capture running buffer. Based on the immobilized ligand response value, theoretical Rmax values were calculated for all analytes. The Rmax values assume 1:1 interaction mechanism. Overnight kinetics was performed for all analytes in the presence of PBS-P. The flow rate of all the solutions was maintained at 30 μL/min. Association and dissociation times used for all analyte injections were 60s, and 300s, respectively. One 20 s pulse of 2 M NaCl was injected for surface regeneration. Analyte concentrations for all analytes were 100 nM down to 3.125 nM (Two fold dilution). Analyte solutions were injected in triplicate. The sensorgrams obtained from the overnight kinetics were evaluated by using 1:1 kinetics model fitting.

Kaplan-Meier analysis of PBX1 expression and patients clinical outcome
Survival curve analysis and corresponding statistics were performed using GraphPad Prism software. In the analysis using the dataset from the TCGA Breast Invasive Carcinoma cohort (n = 408), samples were divided into quartiles based on PBX1 expression, with the lowest 25% of the value assigned as PBX1 low expression and the highest 25% of the value as PBX1 high expression. In analysis using ovarian serous cancer datasets from the Kaplan-Meier (K-M) Plotter portal, auto selection of the best cutoffs was chosen.

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism software version 5.0. All data are presented as mean ± SD. Statistical analysis was performed by 2-tail Student’s t test; p < 0.05 was considered significant.